Tobam Neurocrine Biosciences Inc Transaction History

Tobam

$276 Million
Q3 2025

A detailed history of Tobam transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Tobam holds 5,041 shares of NBIX stock, worth $730,239. This represents 0.26% of its overall portfolio holdings.

Number of Shares

5,041

Previous 9,584 47.4%

Holding current value

$730,239

Previous $1.21 Million 41.24%

% of portfolio

0.26%

Previous 0.47%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	SELL	$123.98 - $146.67 $563,241 - $666,321	-4,543 Reduced 47.4%	5,041 $708,000
Q2 2025 Aug 08, 2025	SELL	$87.54 - $128.18 $1.09 Million - $1.59 Million	-12,428 Reduced 56.46%	9,584 $1.21 Million
Q1 2025 Apr 16, 2025	SELL	$107.22 - $153.29 $992,428 - $1.42 Million	-9,256 Reduced 29.6%	22,012 $2.44 Million
Q4 2024 Jan 28, 2025	SELL	$111.62 - $139.44 $4.69 Million - $5.85 Million	-41,978 Reduced 57.31%	31,268 $4.27 Million
Q3 2024 Oct 09, 2024	SELL	$114.58 - $153.15 $1.97 Million - $2.64 Million	-17,219 Reduced 19.03%	73,246 $8.44 Million

Q2 2024 Jul 29, 2024	SELL	$130.86 - $143.19 $11.5 Million - $12.6 Million	-87,788 Reduced 49.25%	90,465 $12.5 Million
Q1 2024 May 02, 2024	SELL	$130.4 - $143.74 $6.34 Million - $6.98 Million	-48,588 Reduced 21.42%	178,253 $24.6 Million
Q4 2023 Jan 26, 2024	SELL	$106.07 - $132.76 $7.46 Million - $9.34 Million	-70,343 Reduced 23.67%	226,841 $29.9 Million
Q3 2023 Oct 31, 2023	SELL	$94.02 - $117.1 $1.37 Million - $1.7 Million	-14,531 Reduced 4.66%	297,184 $33.4 Million
Q2 2023 Jul 31, 2023	SELL	$89.53 - $104.87 $4.54 Million - $5.32 Million	-50,689 Reduced 13.99%	311,715 $29.4 Million
Q1 2023 May 03, 2023	BUY	$94.11 - $123.02 $7.02 Million - $9.17 Million	74,564 Added 25.9%	362,404 $36.7 Million
Q4 2022 Feb 02, 2023	BUY	$106.72 - $127.06 $103,411 - $123,121	969 Added 0.34%	287,840 $34.4 Million
Q3 2022 Nov 02, 2022	SELL	$92.03 - $107.81 $1.81 Million - $2.12 Million	-19,623 Reduced 6.4%	286,871 $30.5 Million
Q2 2022 Aug 02, 2022	BUY	$75.79 - $100.07 $6.82 Million - $9.01 Million	90,037 Added 41.6%	306,494 $29.9 Million
Q1 2022 Apr 25, 2022	BUY	$72.45 - $94.81 $1.79 Million - $2.34 Million	24,704 Added 12.88%	216,457 $20.3 Million
Q4 2021 Feb 15, 2022	BUY	$79.65 - $106.22 $5.3 Million - $7.07 Million	66,588 Added 53.2%	191,753 $16.3 Million
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $4,222 - $4,852	-49 Reduced 0.04%	125,165 $12 Million
Q2 2021 Aug 11, 2021	BUY	$89.43 - $102.27 $2.67 Million - $3.05 Million	29,810 Added 31.25%	125,214 $12.2 Million
Q1 2021 May 11, 2021	BUY	$87.57 - $119.4 $3.09 Million - $4.21 Million	35,249 Added 58.6%	95,404 $9.28 Million
Q4 2020 Feb 03, 2021	BUY	$86.91 - $108.33 $2.51 Million - $3.13 Million	28,849 Added 92.15%	60,155 $5.77 Million
Q3 2020 Nov 12, 2020	SELL	$96.16 - $135.15 $2.25 Million - $3.16 Million	-23,350 Reduced 42.72%	31,306 $3.01 Million
Q2 2020 Aug 17, 2020	SELL	$85.09 - $130.36 $293,730 - $450,002	-3,452 Reduced 5.94%	54,656 $6.67 Million
Q1 2020 May 07, 2020	BUY	$75.11 - $113.76 $2.73 Million - $4.13 Million	36,315 Added 166.64%	58,108 $5.03 Million
Q4 2019 Feb 10, 2020	BUY	$86.8 - $118.57 $1.53 Million - $2.09 Million	17,614 Added 421.49%	21,793 $2.34 Million
Q3 2019 Nov 12, 2019	BUY	$83.82 - $101.5 $44,340 - $53,693	529 Added 14.49%	4,179 $377,000
Q2 2019 Aug 13, 2019	BUY	$72.24 - $91.27 $36,914 - $46,638	511 Added 16.28%	3,650 $308,000
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $94,885 - $125,304	1,369 Added 77.34%	3,139 $277,000
Q4 2018 Feb 11, 2019	BUY	$68.32 - $124.36 $120,926 - $220,117	1,770 New	1,770 $126,000

Others Institutions Holding NBIX

# of Institutions

725

Shares Held

102M

Call Options Held

230K

Put Options Held

477K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tobam, based on Form 13F filings with the SEC.

News

Stay updated on Tobam with notifications on news.

Account